$4.07
-0.30 (-6.87%)
Open$4.38
Previous Close$4.37
Day High$4.46
Day Low$3.96
52W High$13.50
52W Low$3.50
Volume—
Avg Volume103.1K
Market Cap53.54M
P/E Ratio—
EPS$-3.18
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+363.4% upside
Current
$4.07
$4.07
Target
$18.86
$18.86
$15.04
$18.86 avg
$28.67
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 267.0K | 355.0K | 28.89M |
| Net Income | -34,924,061 | -41,786,300 | 2.55M |
| Profit Margin | -13,086.5% | -12,432.2% | 8.8% |
| EBITDA | -28,805,641 | -36,380,429 | 4.88M |
| Free Cash Flow | — | — | 2.44M |
| Rev Growth | -24.8% | -24.8% | +0.1% |
| Debt/Equity | 1.99 | 1.99 | 0.72 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |